SEC Filing Summary: Ra Medical Systems, Inc. (RMED)
Business Context and Reporting Period
This Form 8-K was filed by Ra Medical Systems, Inc. on April 15, 2022. The registrant is incorporated in Delaware and reports under Commission File Number 001-38677. The company is designated as an emerging growth company. The report addresses corporate governance changes effective April 20, 2022.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition changes and does not contain financial performance data.
Material Changes
The Board of Directors reallocated a Class II director seat to Class III. Specifically:
- Susanne Meline stepped down as a Class II director (term expiring at the 2023 annual meeting).
- Ms. Meline was immediately reappointed as a Class III director (term expiring at the 2024 annual meeting).
- The number of Class III seats was increased from one to two.
- The number of Class II seats was reduced from three to two.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the disclosure of the director reappointment under Item 5.02.
Key Facts for Investor Verification
- Verify the updated composition of the Board of Directors, specifically the shift in class terms for Susanne Meline.
- Confirm the total number of director seats in Class II and Class III following the April 20, 2022 adjustment.
- Note that this filing contains no financial updates; refer to the most recent 10-Q or 10-K for financial performance.